biotech thread - wednesday 31st october , page-34

Hi slura,

I carried out a qualitative analysis on AHZ in October if you are still doing due diligence on the company. I also agree with the content of Purple's post, although I don't expect any CR will be required before Q2/2013.

Revenue growth for the medical device business is looking healthy, and we can probably expect to be a little spoilt with some positive news flow over the next 6+ months, including the announcement of more cardiothoracic surgeons currently seeking authorisation to use CardioCel, and of course the highly anticipated phaseI clinical trial for Prof. Frazer's HSV-2 vaccine. This is the one for investors to watch imo, as there are over 500 million people in the world effected with this virus with no effective treatment available. Pre-clinical data presented last year have also got opinion leaders confident that the same results will be translated into humans, offering prophylactic protection, and a potential cure for those infected by the virus.

500 million people + Social Media = a great investment opportunity. Imo

The CSIRO partnership for stem cell research could be a dark horse, although this collaboration is only at the very early stages of the study cycle.

Plenty of reading material here for you. enjoy.

Allied Health Group - Qualitative Analysis